Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**FYTTD1P1 (Forty-Two-Three Domain Containing 1 Pseudogene 1)** is classified as a pseudogene, meaning it resembles a functional gene but contains mutations or alterations that prevent it from producing functional protein[5][1]. Pseudogenes are often considered non-functional DNA elements, although emerging research suggests that some pseudogenes can regulate gene expression at the RNA level in certain contexts, typically by acting as competing endogenous RNAs or through other regulatory mechanisms[2]. However, there is no documented evidence or literature indicating that FYTTD1P1 acts in such a role or is involved in disease, and it is not established as a receptor, enzyme, or any classic therapeutic target. There is no association of FYTTD1P1 with characterized biological function, disease role, or drug targeting in current genetic databases and scientific literature[5][1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forty-Two-Three Domain Containing 1 Pseudogene 1 (FYTTD1P1).